Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Regorafenib in Node Positive Esophageal Cancer
NCT02234180Phase 2Terminated
- Sponsor
- Academic and Community Cancer Research United
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Academic and Community Cancer Research United. Started Sep 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02234180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234180.